去痰薬市場レポート：2030年までの動向、予測、競合分析

去痰薬の動向と予測

世界の去痰薬市場は、2024年から2030年までのCAGRが4.2%で、2030年までに推定211億米ドルに達すると予測されます。この市場の主な促進要因は、喉の乾燥につながる空咳の発生件数の増加、喘息や慢性閉塞性肺疾患（COPD）のような呼吸器疾患の発生率の上昇、さらに薬剤製剤やデリバリー方法の開発・進歩による去痰薬の性能の向上です。世界の去痰薬市場の将来は、病院薬局、小売店、ドラッグストア、オンライン薬局の各市場における機会によって有望視されています。

セグメント別去痰薬

本調査では、去痰薬の世界市場を薬剤タイプ別、剤形別、製品タイプ別、流通チャネル別、地域別に予測しています。

去痰薬市場の洞察

Lucintelの予測では、分泌促進剤はいくつかの呼吸器疾患の管理に有益であるため、予測期間中はより大きなセグメントであり続けると思われます。

この市場において、小売店は最大のセグメントであり続けると思われます。

北米は、研究開発活動が活発化しており、政府の政策や承認も進んでいることから、予測期間中も最大地域であり続けるでしょう。

よくある質問

Q1.市場規模は：

A1.世界の去痰薬市場は、2030年までに推定211億米ドルに達すると予想されています。

Q2.市場の成長予測は：

A2.世界の去痰薬市場は、2024年から2030年にかけてCAGR 4.2%で成長する見込みです。

Q3.市場の成長に影響を与える主な促進要因は：

A3.この市場の主な促進要因は、喉の乾燥につながる空咳の発生件数の増加、喘息や慢性閉塞性肺疾患（COPD）のような呼吸器疾患の発生率の上昇、さらに薬剤製剤やデリバリー方法の開発や進歩による去痰薬の性能の向上です。

Q4.市場の主要セグメントは：

A4.世界の去痰薬市場の将来は、病院薬局、小売店、ドラッグストア、オンライン薬局の各市場における機会により有望であると思われます。

Q5.市場の主要企業は：

A5.主な去痰薬企業は以下の通りです：

• Abbott Laboratories
• Acella Pharmaceuticals
• AstraZeneca
• Cipla Limited
• Dabur
• Glenmark Pharmaceuticals
• Johnson and Johnson
• Merck
• Novartis International
• Pfizer

Q6.今後、最大となる市場セグメントは：

A6.Lucintelは、分泌促進剤はいくつかの呼吸器疾患の管理に有益であるため、予測期間にわたってより大きなセグメントであり続けると予測しています。

Q7.市場において、今後5年間に最大になると予想される地域は：

A7.北米は、研究開発活動が活発化しており、政府の政策や承認も進んでいることから、予測期間中も最大地域であり続けると思われます。

Q8.レポートのカスタマイズは可能か：

A8.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の去痰薬市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の去痰薬市場の動向（2018～2023年）と予測（2024～2030年）
• 薬剤タイプ別世界の去痰薬市場
  • 分泌促進剤
  • 粘液溶解薬
• 剤形別世界の去痰薬市場
  • 経口固形剤
  • 経口液剤
  • 吸入剤
• 製品タイプ別世界の去痰薬市場
  • 店頭薬 (OTC)
  • 処方薬
• 流通チャネル別世界の去痰薬市場
  • 病院薬局
  • 小売店
  • ドラッグストア
  • オンライン薬局
  • その他

第4章 2018年から2030年までの地域別市場動向と予測分析

• 地域別世界の去痰薬市場
• 北米の去痰薬市場
• 欧州の去痰薬市場
• アジア太平洋の去痰薬市場
• その他地域の去痰薬市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 薬剤タイプ別の世界の去痰薬市場の成長機会
  • 剤形別の世界の去痰薬市場の成長機会
  • 製品タイプ別の世界の去痰薬市場の成長機会
  • 流通チャネル別の世界の去痰薬市場の成長機会
  • 地域別の世界の去痰薬市場の成長機会
• 世界の去痰薬市場の新たな動向
• 戦略分析
  • 新製品開発
  • 世界の去痰薬市場の生産能力拡大
  • 世界の去痰薬市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Abbott Laboratories
• Acella Pharmaceuticals
• AstraZeneca
• Cipla Limited
• Dabur
• Glenmark Pharmaceuticals
• Johnson and Johnson
• Merck
• Novartis International
• Pfizer

Expectorant Drug Trends and Forecast

The future of the global expectorant drug market looks promising with opportunities in the hospital pharmacy, retail store, drug store, and online pharmacy markets. The global expectorant drug market is expected to reach an estimated $21.1 billion by 2030 with a CAGR of 4.2% from 2024 to 2030. The major drivers for this market are growing number of incidences of dry cough that lead to dry throats, rising rates of respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), as well as, improvements in the performance of expectorant drugs owing to developments and advances in drug formulation and delivery methods.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Expectorant Drug by Segment

The study includes a forecast for the global expectorant drug by drug type, dosage form, product type, distribution channel, and region.

Expectorant Drug Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

• Secretion Enhancer
• Mucolytics

Expectorant Drug Market by Dosage Form [Shipment Analysis by Value from 2018 to 2030]:

• Oral Solid
• Oral Liquid
• Inhalant

Expectorant Drug Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

• Over-The-Counter
• Prescription Drug

Expectorant Drug Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacies
• Retail Store
• Drug Store
• Online Pharmacies
• Others

Expectorant Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Expectorant Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies expectorant drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the expectorant drug companies profiled in this report include-

• Abbott Laboratories
• Acella Pharmaceuticals
• AstraZeneca
• Cipla Limited
• Dabur
• Glenmark Pharmaceuticals
• Johnson and Johnson
• Merck
• Novartis International
• Pfizer

Expectorant Drug Market Insights

Lucintel forecasts that secretion enhancer will remain larger segment over the forecast period due to they are beneficial in the management of several respiratory conditions.

Within this market, retail store will remain the largest segment.

North America will remain the largest region over the forecast period due to growing number of research and development activities, along with government policies and approvals in the region.

Features of the Global Expectorant Drug Market

Market Size Estimates: Expectorant drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Expectorant drug market size by drug type, dosage form, product type, distribution channel, and region in terms of value ($B).

Regional Analysis: Expectorant drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug type, dosage form, product type, distribution channel, and regions for the expectorant drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the expectorant drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the expectorant drug market size?

Answer: The global expectorant drug market is expected to reach an estimated $21.1 billion by 2030.

Q2. What is the growth forecast for expectorant drug market?

Answer: The global expectorant drug market is expected to grow with a CAGR of 4.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the expectorant drug market?

Answer: The major drivers for this market are growing number of incidences of dry cough that lead to dry throats, rising rates of respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), as well as, improvements in the performance of expectorant drugs owing to developments and advances in drug formulation and delivery methods.

Q4. What are the major segments for expectorant drug market?

Answer: The future of the global expectorant drug market looks promising with opportunities in the hospital pharmacy, retail store, drug store, and online pharmacy markets.

Q5. Who are the key expectorant drug market companies?

Answer: Some of the key expectorant drug companies are as follows:

• Abbott Laboratories
• Acella Pharmaceuticals
• AstraZeneca
• Cipla Limited
• Dabur
• Glenmark Pharmaceuticals
• Johnson and Johnson
• Merck
• Novartis International
• Pfizer

Q6. Which expectorant drug market segment will be the largest in future?

Answer: Lucintel forecasts that secretion enhancer will remain larger segment over the forecast period due to they are beneficial in the management of several respiratory conditions.

Q7. In expectorant drug market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing number of research and development activities, along with government policies and approvals in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the expectorant drug market by drug type (secretion enhancer and mucolytics), dosage form (oral solid, oral liquid, and inhalant), product type (over-the-counter and prescription drug), distribution channel (hospital pharmacies, retail store, drug store, online pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Expectorant Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Expectorant Drug Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Expectorant Drug Market by Drug Type
  • 3.3.1: Secretion Enhancer
  • 3.3.2: Mucolytics
• 3.4: Global Expectorant Drug Market by Dosage Form
  • 3.4.1: Oral Solid
  • 3.4.2: Oral Liquid
  • 3.4.3: Inhalant
• 3.5: Global Expectorant Drug Market by Product Type
  • 3.5.1: Over-The-Counter
  • 3.5.2: Prescription Drug
• 3.6: Global Expectorant Drug Market by Distribution Channel
  • 3.6.1: Hospital Pharmacies
  • 3.6.2: Retail Store
  • 3.6.3: Drug Store
  • 3.6.4: Online Pharmacies
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Expectorant Drug Market by Region
• 4.2: North American Expectorant Drug Market
  • 4.2.1: North American Expectorant Drug Market by Drug Type: Secretion Enhancer and Mucolytics
  • 4.2.2: North American Expectorant Drug Market by Distribution Channel: Hospital Pharmacies, Retail Store, Drug Store, Online Pharmacies, and Others
• 4.3: European Expectorant Drug Market
  • 4.3.1: European Expectorant Drug Market by Drug Type: Secretion Enhancer and Mucolytics
  • 4.3.2: European Expectorant Drug Market by Distribution Channel: Hospital Pharmacies, Retail Store, Drug Store, Online Pharmacies, and Others
• 4.4: APAC Expectorant Drug Market
  • 4.4.1: APAC Expectorant Drug Market by Drug Type: Secretion Enhancer and Mucolytics
  • 4.4.2: APAC Expectorant Drug Market by Distribution Channel: Hospital Pharmacies, Retail Store, Drug Store, Online Pharmacies, and Others
• 4.5: ROW Expectorant Drug Market
  • 4.5.1: ROW Expectorant Drug Market by Drug Type: Secretion Enhancer and Mucolytics
  • 4.5.2: ROW Expectorant Drug Market by Distribution Channel: Hospital Pharmacies, Retail Store, Drug Store, Online Pharmacies, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Expectorant Drug Market by Drug Type
  • 6.1.2: Growth Opportunities for the Global Expectorant Drug Market by Dosage Form
  • 6.1.3: Growth Opportunities for the Global Expectorant Drug Market by Product Type
  • 6.1.4: Growth Opportunities for the Global Expectorant Drug Market by Distribution Channel
  • 6.1.5: Growth Opportunities for the Global Expectorant Drug Market by Region
• 6.2: Emerging Trends in the Global Expectorant Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Expectorant Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Expectorant Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abbott Laboratories
• 7.2: Acella Pharmaceuticals
• 7.3: AstraZeneca
• 7.4: Cipla Limited
• 7.5: Dabur
• 7.6: Glenmark Pharmaceuticals
• 7.7: Johnson and Johnson
• 7.8: Merck
• 7.9: Novartis International
• 7.10: Pfizer